NCT03177902Recruiting
Evaluation of Thyroid Abnormity Incidence and Thyroid Toxicity During Chemotherapy Among Newly Diagnosed Breast Cancer
A Prospective Study to Assess Both Thyroid Abnormity Incidence In Chinese Women With Newly Diagnosed Breast Cancer and Thyroid Toxicity of Breast Cancer Patients Undergoing Chemotherapy
Source: ClinicalTrials.gov · Last updated 4 Sept 2026
Brief summary (registry, in English)
Breast cancer is one of the most common cancers in China. Even though advances in the field of breast cancer therapeutics, chemotherapy remains the mainstay therapeutic modality. The cytotoxic therapies are generally associated with some immediate or otherwise delayed side effects, such as adverse effects on gastrointestinal, hepatic, renal and hematological systems. The effect of chemotherapy on endocrine system, however, is comparatively less envisaged. Several epidemiological studies show a positive association between plasma thyroid hormones levels and breast cancer risk. Thyroid dysfunction is emerging as a variably common endocrine toxicity of several anticancer drugs. Due to the scarcity of data on the functioning of thyroid gland during chemotherapy in a large scale group, the present study was aimed to investigate the incidence of thyroid abnormity in Chinese women with newly diagnosed breast cancer, and also the effects of chemotherapy on thyroid gland functions or structure in these breast cancer patients undergoing at least four cycles of chemotherapy.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 400 (estimated)
- First submitted
- 28 May 2017
- Start date
- 4 Jun 2017
- Primary completion date
- 30 Apr 2027
- Lead sponsor
- The First Affiliated Hospital of Bengbu Medical University
- Diseases
- Thyroid cancer
- NCT number
- NCT03177902
What you commit to
- Study type: Observational
- Planned participants: 400
- From 4 Jun 2017 to the primary completion date, 30 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment with drugs capable of influencing thyroid gland functions within 3 months prior to study entry;
- Current, recent (within 4 weeks prior to study entry), or planned participation in any other clinical trials;
Other illness
- History of other malignancy or secondary breast cancer;
- History of thyroid disease;
- History of drug addiction or abuse;
- History of immunodeficiency disease;
- Nonmeasurable disease such as un-controlled diabetes, severe cardiovascular and cerebrovascular diseases;
Other
- Pregnancy or lactation;
- Inability to understand and agree to informed consent.
Who the study is looking for
- Female patients with histologically or cytologically proven primary breast cancer;
- Age \>18 years;
- ECOG Performance Status: 0-2;
- Life Expectancy: 3 months or more;
- No previous anti-cancer therapy;
- Be willing to undergo at least four cycles of anthracycline or taxane-based chemotherapy;
- Adequate hematological, liver, and kidney functions.
Age in the registry: 18 years to 85 years · Sex: Female
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College Coordinator of this site? Confirm its status | Bengbu | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.